The Use of Nafamostat Mesilate as an Anticoagulant during Continuous Renal Replacement Therapy for Children with a High Risk of Bleeding
1
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Purpose: Nafamostat mesilate (NM), a synthetic serine protease inhibitor, has been investigated as an anticoagulant for adult patients with a high risk of bleeding, who need chronic renal replacement therapy (CRRT). However, little is known about the use of NM as an anticoagulant in pediatric CRRT. The aim of this study was to evaluate the ideal dosage, efficacy, and safety of NM in pediatric CRRT. Methods: We conducted a retrospective study of 40 pediatric patients who had undergone at least 24 h of venovenous CRRTs between January 2011 and October 2013. We divided the patients according to risk of bleeding. Those at high risk received no anticoagulation (group 1) or NM as an anticoagulant (group 2), while those at low risk received heparin (group 3). Results: Forty patients (25 male and 15 female; mean age, 8.2±6.6 years) were enrolled. The mean duration of CRRT was 13.0 days, and the survival rate was 57.5%. The mean hemofilter lifespan was 39.3 h in group 1 and 11.3 h in group 3. In group 2, hemofilter lifespan was extended from 7.5 h to 27.4 h after the use of NM (P =0.001). The mean hemofilter lifespan with NM was greater than with heparin (P =0.018). No patient experienced a major bleeding event during treatment with NM. Conclusion: NM may be a good alternative anticoagulant in pediatric patients with a high risk of bleeding requiring CRRT, and is not associated with bleeding complications.
Abstract
Purpose: Nafamostat mesilate (NM), a synthetic serine protease inhibitor, has been investigated as an anticoagulant for adult patients with a high risk of bleeding, who need chronic renal replacement therapy (CRRT). However, little is known about the use of NM as an anticoagulant in pediatric CRRT. The aim of this study was to evaluate the ideal dosage, efficacy, and safety of NM in pediatric CRRT. Methods: We conducted a retrospective study of 40 pediatric patients who had undergone at least 24 h of venovenous CRRTs between January 2011 and October 2013. We divided the patients according to risk of bleeding. Those at high risk received no anticoagulation (group 1) or NM as an anticoagulant (group 2), while those at low risk received heparin (group 3). Results: Forty patients (25 male and 15 female; mean age, 8.2±6.6 years) were enrolled. The mean duration of CRRT was 13.0 days, and the survival rate was 57.5%. The mean hemofilter lifespan was 39.3 h in group 1 and 11.3 h in group 3. In group 2, hemofilter lifespan was extended from 7.5 h to 27.4 h after the use of NM (P =0.001). The mean hemofilter lifespan with NM was greater than with heparin (P =0.018). No patient experienced a major bleeding event during treatment with NM. Conclusion: NM may be a good alternative anticoagulant in pediatric patients with a high risk of bleeding requiring CRRT, and is not associated with bleeding complications.
참고문헌 (24)
- Kramer P, "Arteriovenous haemofilteration: A new and simple method for treatment of over-hydrated patients resistant to diuretics", Klin Wochenschr, 55, pp.1121~1122 (1997)
- Ronco C, "Treatment of acute renal failure in newborns by continuous arteriovenous hemofiltration", Kidney Int, 29, pp.908~915 (1986)
- Scott M, "Continuous renal replacement therapy in children", Pediatr Nephrol, 27, pp.2007~2016 (2012)
- Flynn JT, "Choice of dialysis modality for management of pediatric acute renal failure", Pediatr Nephrol, 17, pp.61~69 (2002)
- Vasudevan A, "Modality of choice for renal replacement thepray for children with acute kidney injury: Results of a survey", Indian J Nephrol, 22, pp.121~124 (2012)
- Scott Walters, "Dialysis and pediatric acute kidney injury: choice of renal support modality", Pediatr Nephrol, 24, pp.37~48 (2009)
- Michael Joannidis, "Clinical review: Patency of the circuit in continuous renal replacement therapy", Critical Care, 11, pp.218~ (2007)
- Baek NN, "The role of nafamostat mesylate in continuous renal replacement therapy among patients at high risk of bleeding", Ren Fail, 34, pp.279~285 (2012)
- Yang JW, "Superior outcome of nafamostat mesilate as an anticoagulant in patients undergoing maintenance hemodialysis with intracerebral hemorrhage", Ren Fail, 31, pp.668~675 (2009)
- R. L. Mehta, "Anticoagulation in severely ill patients treated with continuous hemofiltration", Nefrologia, 12, pp.287~294 (1992)
- Hu ZJ, "Time course of activated coagulation time at various site during continuous hemodiafiltration using nafamostat mesilate", Intensive Care Med, 25, pp.524~527 (1999)
- Ohtake Y, "Nafamostat mesylate as anticoagulant in continuous hemofiltration and continuous hemidiafiltration", Contrib Nephrol, 93, pp.215~217 (1991)
- Hiroma T, "Continuous venovenous hemofiltration in neonatal onset hyperammonemia", Am J Perinatol, 19, pp.221~224 (2002)
- Tolwani AJ, "Anticoagulation for continuous renal replacement therapy", Semin Dial, 22, pp.141~145 (2009)
- Davis H, "Maintaining the CRRT circuit: non-anticoagulant alternatives", Aust Crit Care, 19, pp.133~138 (2006)
- Maruyama Y, "Nafamostat mesilate as an anticoagulation during continuous veno-venous hemodialysis: a three-year retrospective cohort study", Int J Artif Organs, 34, pp.571~576 (2011)
- Davenport A, "Alternatives to standard unfractionated heparin for pediatric hemodialysis treatments", Pediatr Nephrol, 27, pp.1869~1879 (2012)
- Nagava M, "Application of a new anticoagulant (Nafamostat mesilate) to control hemorrhagic complications during extracorporeal membrane oxygenation-a preliminary report", J Pediatr Surg, 32, pp.531~535 (1997)
- Maruyama H, "Anaphylactoid reaction induced by nafamostat mesilate in a hemodialysis patient", Nephron, 74, pp.468~469 (1996)
- Higuchi N, "Anaphylactoid reaction induced by a protease inhibitor, nafamostat mesilate, following nine administrations in a hemodialysis patient", Nephron, 85, pp.400~401 (2000)
- Yamazato M, "Severe abdominal pain associated with allergic reaction to nafamostat mesilate in a chronic hemodialsysis patient", Intern Med, 41, pp.864~866 (2002)
- Muto S, "Mechanisms of hyperkalemia caused by nafamostat mesilate", Gen Pharmacol, 26, pp.1627~1632 (1995)
- Ookawara S, "Additional mechanisms of nafamostat mesilate-associated hyperkalemia", Eur J Clin Pharmacol, 51, pp.149~151 (1996)
- Kammerl MC, "Extracorporal therapy with AN 69 membranes in combination with ACE inhibiton causing severe anaphylactoid reactions:still a current problem?", Clin Nephrol, 53, pp.486~486 (2000)